These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25809305)

  • 1. Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?
    Bielekova B; McDermott MP
    Neurology; 2015 Apr; 84(16):1620-1. PubMed ID: 25809305
    [No Abstract]   [Full Text] [Related]  

  • 2. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
    Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L
    Neurology; 2015 Apr; 84(16):1639-43. PubMed ID: 25809304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fingolimod in relapsing-remitting multiple sclerosis.
    Sorensen PS
    Lancet Neurol; 2014 Jun; 13(6):526-7. PubMed ID: 24685277
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
    Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
    [No Abstract]   [Full Text] [Related]  

  • 6. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis.
    van Rossum JA; Looysen EE; Daniels JM; Killestein J
    Mult Scler; 2014 Nov; 20(13):1792-3. PubMed ID: 24866203
    [No Abstract]   [Full Text] [Related]  

  • 9. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
    Gábor L
    Ideggyogy Sz; 2014 Mar; 67(3-4):141. PubMed ID: 26118259
    [No Abstract]   [Full Text] [Related]  

  • 10. Homing frequency of human T cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade.
    Mehling M; Brinkmann V; Burgener AV; Gubser P; Luster AD; Kappos L; Hess C
    J Allergy Clin Immunol; 2013 May; 131(5):1440-3.e7. PubMed ID: 23434284
    [No Abstract]   [Full Text] [Related]  

  • 11. Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy.
    Yokoseki A; Saji E; Arakawa M; Hokari M; Ishiguro T; Yanagimura F; Ishihara T; Okamoto K; Nishizawa M; Kawachi I
    Mult Scler; 2013 Aug; 19(9):1230-3. PubMed ID: 23519973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting of subgroup analyses from clinical trials.
    Sormani MP; Bruzzi P
    Lancet Neurol; 2012 Sep; 11(9):747; author reply 747-8. PubMed ID: 22898729
    [No Abstract]   [Full Text] [Related]  

  • 13. Indirect comparisons of treatment effects in multiple sclerosis.
    Sormani MP; Signori A
    Eur J Clin Pharmacol; 2012 Aug; 68(8):1227-8; author reply 1225-6. PubMed ID: 22374347
    [No Abstract]   [Full Text] [Related]  

  • 14. Azathioprine in multiple sclerosis.
    Invernizzi P; Benedetti MD; Poli S; Monaco S
    Mini Rev Med Chem; 2008 Aug; 8(9):919-26. PubMed ID: 18691149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MS clinical trials: what can subgroup analyses teach us?
    Rudick RA
    Lancet Neurol; 2012 May; 11(5):386-8. PubMed ID: 22494954
    [No Abstract]   [Full Text] [Related]  

  • 17. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
    Tanaka M; Park K; Tanaka K
    Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral cladribine and fingolimod for relapsing multiple sclerosis.
    Mann H
    N Engl J Med; 2010 May; 362(18):1738; author reply 1739-40. PubMed ID: 20445188
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Vasiliou S
    Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.